Literature DB >> 13680175

High spontaneous colony growth in chronic myelomonocytic leukemia correlates with increased disease activity and is a novel prognostic factor for predicting short survival.

V Sagaster1, L Ohler, A Berer, E Kabrna, P Ofner, K Lechner, K Geissler.   

Abstract

We have originally shown that spontaneous granulocyte/macrophage colony (CFU-GM) formation in semisolid medium is a characteristic in vitro feature of chronic myelomonocytic leukemia (CMML). However, the clinical significance of spontaneous CFU-GM growth in CMML is unknown so far. CFU-GM growth characteristics were studied in semisolid cultures in the absence of exogenous cytokines using peripheral blood mononuclear cells in 30 patients with CMML at first presentation. The median number of CFU-GM/10(5) MNC of all patients was 48.5 (range 0-622) with 18 patients having colony numbers below 100 (low CFU-GM growth) and 12 patients above 100 (high CFU-GM growth). Kaplan-Meier analysis revealed that patients with high CFU-GM growth had a significantly shorter survival than patients with low CFU-GM growth (median 6.5 vs. 44.5 months, p<0.00002). The probability of survival after 2 years was 60.5% for patients with low colony growth but 0% in those with high colony formation. Patients with CFU-GM >100 had a significantly higher WBC count, a higher LDH, and a higher number of blast cells in blood and bone marrow than patients with low colony growth. Moreover, patients with high colony growth had more often splenomegaly and lower platelet counts. In seven patients, in whom semisolid in vitro cultures were performed after transformation into RAEBT/AML, spontaneous colony growth was significantly increased as compared to CFU-GM growth in patients before transformation (median number/10(5) MNC 533, range 212-4553, p<0.005). This study demonstrates that high (>100) spontaneous CFU-GM formation in CMML at presentation correlates with increased disease activity and represents a novel and important prognostic factor predicting for short survival of CMML patients.

Entities:  

Mesh:

Year:  2003        PMID: 13680175     DOI: 10.1007/s00277-003-0743-9

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  4 in total

1.  Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?

Authors:  Klaus Geissler; Eva Jäger; Agnes Barna; Thamer Sliwa; Paul Knöbl; Ilse Schwarzinger; Heinz Gisslinger; Peter Valent
Journal:  Haematologica       Date:  2016-12       Impact factor: 9.941

2.  Chronic myelomonocytic leukemia patients with RAS pathway mutations show high in vitro myeloid colony formation in the absence of exogenous growth factors.

Authors:  K Geissler; E Jäger; A Barna; T Alendar; E Ljubuncic; T Sliwa; P Valent
Journal:  Leukemia       Date:  2016-08-18       Impact factor: 11.528

3.  Multistep pathogenesis of chronic myelomonocytic leukemia in patients.

Authors:  Klaus Geissler; Eva Jäger; Agnes Barna; Michael Gurbisz; Renate Marschon; Temeida Graf; Thomas Nösslinger; Michael Pfeilstöcker; Sigrid Machherndl-Spandl; Reinhard Stauder; Armin Zebisch; Heinz Sill; Leopold Öhler; Rajko Kusec; Gregor Hoermann; Peter Valent
Journal:  Eur J Haematol       Date:  2022-03-23       Impact factor: 3.674

4.  Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia.

Authors:  Klaus Geissler; Eva Jäger; Agnes Barna; Michael Gurbisz; Temeida Graf; Elmir Graf; Thomas Nösslinger; Michael Pfeilstöcker; Sigrid Machherndl-Spandl; Reinhard Stauder; Armin Zebisch; Heinz Sill; Leopold Öhler; Rajko Kusec; Gregor Hörmann; Peter Valent
Journal:  Int J Mol Sci       Date:  2020-08-22       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.